Evan Lippman

Evan Lippman joined Alnylam in September of 2022 as Chief Corporate Development and Strategy Officer bringing with him many years of experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.

Evan joined Alnylam from Intima Bioscience where he served as President and Chief Operating Officer. Prior to Intima, he was Senior Vice President Head of Corporate Development, M&A and Valuation for Takeda Pharmaceuticals for nearly five years. In this position he was responsible for developing, structuring, and negotiating global acquisitions, divestments, and commercially focused licensing/strategic collaborations.

Before his time at Takeda, Evan was Chief Business and Financial Officer of Aileron Therapeutics, General Manager at both EMD Serono and AstraZeneca and was at Pfizer as a senior business development executive.

Evan holds an MBA in Finance from Cornell University.